Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

被引：36

作者：

Usher, Cara ^{[1
]}

Tilson, Lesley ^{[1
]}

Olsen, Jens ^{[2
]}

Jepsen, Martin ^{[3
]}

Walsh, Cathal ^{[1
,4
,5
]}

Barry, Michael ^{[1
]}

机构：

[1] St James Hosp, Natl Ctr Pharmacoecon, Dublin 8, Ireland

[2] Tech Univ Denmark, Ctr Appl Hlth Serv Res & Technol Assessment, DK-5000 Odense C, Denmark

[3] Statens Serum Inst, Dept Epidemiol, DK-2300 Copenhagen S, Denmark

[4] Univ Dublin Trinity Coll, Dept Stat, Dublin 2, Ireland

[5] Univ Coll Dublin, UCD Sch Publ Hlth & Populat Sci, Dublin 4, Ireland

来源：

VACCINE | 2008年 / 26卷 / 44期

关键词：

HPV vaccination; Cost effectiveness; Decision maker;

D O I：

10.1016/j.vaccine.2008.07.098

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated the cost-effectiveness of combining a cervical cancer screening programme with a national HPV vaccination programme compared to a screening programme alone to prevent cervical dysplasia and cervical cancer related to HPV types 16 and 18 in the Irish healthcare setting. The incremental cost effectiveness of vaccination strategies for 12-year-old females (base-case) and 12-26-year-old catch-up vaccination strategies were examined. The base-case incremental cost-effectiveness ratio was (sic)17,383/LYG. Using a probabilistic sensitivity analysis about the base-case, the 95% CI for cost per LYG was ((sic)3400 to E38,400). This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：5654 / 5661

页数：8

共 50 条

[1] COST-EFFECTIVENESS OF A HUMAN PAPILLOMAVIRUS VACCINE IN REDUCING THE RISK OF CERVICAL CANCER IN IRELAND USING A TRANSMISSION DYNAMIC MODEL
Usher, C.
Tilson, L.
Olsen, J.
Jepsen, Rudbeck M.
Walsh, C.
Barry, M.
VALUE IN HEALTH, 2008, 11 (06) : A357 - A357
[2] ESTIMATING THE POTENTIAL COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION IN GERMANY USING A DYNAMIC TRANSMISSION MODEL
Damm, O.
Horn, J.
Kretzschmar, M.
Delere, Y.
Kaufmann, A. M.
Wichmann, O.
Kraemer, A.
Greiner, W.
Mikolajczyk, R.
VALUE IN HEALTH, 2011, 14 (07) : A452 - A452
[3] COST-EFFECTIVENESS OF VARIOUS COMBINATIONS OF HUMAN PAPILLOMAVIRUS (HPV)-BASED TESTING, INCLUDING GENOTYPING FOR HPV 16/18, FOR CERVICAL CANCER SCREENING
Huh, W.
Williams, E.
Bramley, T.
Huang, J.
Poulios, N.
VALUE IN HEALTH, 2013, 16 (03) : A142 - A143
[4] COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE FOR PREVENTION OF CERVICAL CANCER IN TAIWAN
Liu, P. H.
Wang, J. D.
VALUE IN HEALTH, 2009, 12 (03) : A46 - A46
[5] Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model
Schobert, Deniz
Remy, Vanessa
Schoeffski, Oliver
HEALTH ECONOMICS REVIEW, 2012, 2
[6] Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model
Deniz Schobert
Vanessa Remy
Oliver Schoeffski
Health Economics Review, 2 (1)
[7] Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
Goldie, SJ
Kohli, M
Grima, D
Weinstein, MC
Wright, TC
Bosch, FX
Franco, E
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (08): : 604 - 615
[8] Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
Zoltán Vokó
László Nagyjánosi
Zoltán Kaló
BMC Public Health, 12
[9] Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
Voko, Zoltan
Nagyjanosi, Laszlo
Kalo, Zoltan
BMC PUBLIC HEALTH, 2012, 12
[10] Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
Bogaards, Johannes A.
Van Der Weele, Pascal
Woestenberg, Petra J.
Van Benthem, Birgit H. B.
King, Audrey J.
JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (07): : 1141 - 1146

← 1 2 3 4 5 →